Adaptimmune Therapeutics plc (ADAPY)
$0.03+0.00%Close
BUYCRISIS · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8M
- Beta
- 0.82
- P/E (TTM)
- -0.10
- Short % float
- 0.46%
- Days to cover
- 2.1
- SI change
- -0.2%
- 1W
- -25.00%
- 1M
- +50.00%
- vs SPY 1W
- -26.16%
- vs SPY 1M
- +47.01%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on ADAPY?
- LOPJLB’s latest quantitative signal on Adaptimmune Therapeutics plc (ADAPY) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is ADAPY in?
- Adaptimmune Therapeutics plc (ADAPY) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Adaptimmune Therapeutics plc (ADAPY) do?
- Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, un…